ANI Pharmaceuticals Reports 53.6% Revenue Growth to $227.8 Million in Latest Quarter

ANI Pharmaceuticals, Inc. reported significant financial growth in its latest quarterly results, with net revenues reaching $227.8 million for the three months ended September 30, 2025, compared to $148.3 million for the same period in 2024, marking a 53.6% increase. The company's net income for the quarter was $26.6 million, a substantial turnaround from a net loss of $24.2 million in the prior year. For the nine months ending September 30, 2025, total revenues were $636.3 million, up 50.1% from $423.8 million in the same period last year, driven by strong sales in both the Rare Disease and Generics segments.

The increase in revenue was largely attributed to the acquisition of Alimera Sciences, which added new products ILUVIEN and YUTIQ to ANI's portfolio. The Rare Disease segment saw a remarkable 104.4% increase in revenues, totaling $291.4 million, primarily due to a full quarter of sales from ILUVIEN and increased demand for Cortrophin Gel. The Generics segment also performed well, with revenues rising 25.2% to $295.9 million, driven by new product launches and increased volumes.

In terms of operational developments, ANI's acquisition of Alimera was finalized on September 16, 2024, and has since expanded the company's market presence, particularly in Europe. The company has also transitioned its promotional efforts from YUTIQ to ILUVIEN, which now includes an expanded label for treating chronic non-infectious uveitis. Additionally, ANI has made strategic investments in its manufacturing capabilities, including a new lease for office space in Princeton, New Jersey, to support its growing operations.

The company reported a total operating income of $36.2 million for the third quarter, a significant improvement from an operating loss of $20.5 million in the same quarter of 2024. This improvement was supported by a decrease in total operating expenses, which fell to $98.2 million from $105.8 million year-over-year. The reduction in expenses was primarily due to lower transaction and integration costs associated with the Alimera acquisition, despite increases in research and development and selling, general, and administrative expenses.

Looking ahead, ANI Pharmaceuticals anticipates continued growth driven by its Rare Disease and Generics segments, with plans to further expand its product offerings and market reach. The company has expressed confidence in its financial resources, including cash on hand and available credit, to meet its operational needs and support future growth initiatives.